New vaccine protects against parvovirus B2

In September 2017, the Food and Drug Administration approved a new adjuvanted polio vaccine for use in the U.S. According to the CDC, these viruses are the most infectious known to man.

They are viral causes of a pneumonia-like illness. Some patients with Coronavirus experience a fever, headache, a body ache, tiredness and muscle weakness. One person died in the late 1970s in Phoenix, Arizona.

The vaccine would cover either A or B strain of the virus, according to the US Department of Health and Human Services. The shot would provide protection against viruses, but it wouldn’t protect against one specific strain.

The vaccine now also contains the live polio virus, meaning that it does not completely shield children from disease.

First, infected people can be vaccinated with the vaccination. Vaccine is not associated with risk of acute encephalitis or meningitis and can be given to children two years old or older. The live vaccine is designed to protect children from secondary infection by viruses resistant to the vaccine. It is not recommended for children younger than 2 or adults over age 50.

Meanwhile, the WHO estimates that there are 15,000 new cases of Coronavirus yearly in 16 countries, and close to 600 deaths. The US Centers for Disease Control and Prevention said that the proportion of Coronavirus-related hospitalizations has increased over the past decade to its highest level in the last two years. Most people with Coronavirus enter hospital either with Coronavirus or another viral infection, said the CDC. Most people in the U.S. who have Coronavirus are hospitalized as a result of a non-medical related condition.

The FDA review of the vaccine will be reviewed over the next year. While it is not yet available for use in the U.S., experts are looking forward to the expansion of the vaccine’s protection.

Leave a Comment